

2. Rascado Sedes P, Ballesteros Sanz MA, Bodí Saera MA, Carrasco Rodríguez-Rey LF, Castellanos Ortega A, Catalán González M, et al. Plan de contingencia para los servicios de medicina intensiva frente a la pandemia COVID-19. *Med Intensiva*. 2020, <http://dx.doi.org/10.1016/j.medin.2020.03.006>. S0210-5691(20)30095-4.
3. Rubio O, Estella A, Cabre L, Saralegui-Reta I, Martín MC, Zapata L, et al. Recomendaciones éticas para la toma de decisiones difíciles en las unidades de cuidados intensivos ante la situación excepcional de crisis por la pandemia por COVID-19: revisión rápida y consenso de expertos. *Med Intensiva*. 2020, <http://dx.doi.org/10.1016/j.medin.2020.04.006>. S0210-5691(20)30110-8.
4. Ballesteros Sanz MÁ, Hernández-Tejedor A, Estella Á, Jiménez Rivera JJ, González de Molina Ortiz FJ, Sandiumenge Camps A, et al. Recomendaciones de «hacer» y «no hacer» en el tratamiento de los pacientes críticos ante la pandemia por coronavirus causante de COVID-19 de los Grupos de Trabajo de la Sociedad Española de Medicina Intensiva, Crítica y Unidades Coronarias (SEMICYUC). *Med Intensiva*. 2020, <http://dx.doi.org/10.1016/j.medin.2020.04.001>. S0210-5691(20)30098-X.
5. Cinesi Gómez C, Peñuelas Rodríguez Ó, Luján Torné ML, Egea Santaolalla C, Masa Jiménez JF, García Fernández J, et al. Recomendaciones de consenso respecto al soporte respiratorio no invasivo en el paciente adulto con insuficiencia respiratoria aguda secundaria a infección por SARS-CoV-2. *Rev Esp Anestesiología y Reanimación*. 2020;67:261–70, <http://dx.doi.org/10.1016/j.redar.2020.03.006>.

Á. Estella^{a,b}

^a Servicio de Medicina Intensiva, Hospital Universitario de Jerez, Cádiz, Spain

^b Departamento de Medicina, Universidad de Cádiz, Cádiz, Spain

E-mail address: litoestella@hotmail.com

2173-5727/ © 2020 Elsevier España, S.L.U. and SEMICYUC. All rights reserved.

SEDAR-SEMICYUC consensus on the management of haemostasis disorders in severe COVID-19 patients[☆]



Consenso SEDAR-SEMICYUC sobre el manejo de las alteraciones de la hemostasia en los pacientes COVID-19 graves

Dear Editor,

Infection due to the SARS-CoV-2 coronavirus, which causes COVID-19, tends to predispose patients to hypercoagulability, with an increased risk of thrombotic disease of a multifactor origin. In view of the need to establish a series of recommendations for the management of coagulation disorders in severe COVID-19 patients, the working groups of the Spanish Society of Anesthesia-Resuscitation and Pain Therapy (*Sociedad Española de Anestesiología-Reanimación y Terapéutica del Dolor* [SEDAR]) and the Spanish Society of Intensive and Critical Care Medicine and Coronary Units (*Sociedad Española de Medicina Intensiva, Crítica y Unidades Coronarias* [SEMICYUC]) decided to join our forces and knowledge and develop a consensus document with the aim of providing guidelines for dealing with these patients. As the result of intense work, with the posterior participation of review committees from both Societies, a manuscript was developed that has just been published by the *Revista Española de Anestesiología y Reanimación* (REDAR).¹ For different reasons unrelated to the authors, joint and simultaneous publication in *MEDICINA INTENSIVA* has not been possible. We believe that the most important aspect of any article – and particularly of a consensus document – is its diffusion for knowledge and subsequent clinical application in

those cases where it is indicated. We therefore would like to highlight some essential aspects of the mentioned document (Fig. 1), and invite those readers who are interested to consult the full open-access original on the website of the REDAR.

Thrombotic risk in COVID-19 patients:

- Assessment of thrombotic and bleeding risk is recommended in all COVID-19 patients in which the seriousness of the disease requires admission to hospital.
- Thrombophylaxis is recommended in all admitted patients, with low molecular weight heparin (LMWH) being the drug of choice.
- In those patients in which a procoagulant profile is confirmed, elevation of the LMWH dose from prophylactic (40-60 mg sc/24 h) to intermediate levels (100 IU/kg/24 h) is suggested, particularly in patients admitted to the Intensive Care Unit (ICU) and subjected to mechanical ventilation.
- Elevation of the LMWH dose from intermediate to therapeutic levels (150 IU/kg/24 h or 100 IU/kg/12 h) is suggested in those cases where pulmonary thromboembolism is suspected (e.g., sudden worsening of oxygenation or a sharp and unexplained drop in blood pressure) and no firm diagnosis can be established.
- Testing to confirm pulmonary thromboembolism is recommended in suspect cases due to progression of the hemostatic parameters (fundamentally D dimer) or on the basis of the clinical course of the patient, whenever possible. If confirmation is established, anticoagulation with LMWH is recommended as standard treatment.

Adjustment of anticoagulant and antiplatelet medication:

- The maintenance of anticoagulation is recommended where required, preferably prescribing LMWH at therapeutic doses.
- The maintenance of antiplatelet treatment is recommended, administering acetylsalicylic acid in those

[☆] Please cite this article as: Llaou JV, Ferrandis R, Sierra P, Hidalgo F, Cassinello C, Gómez-Luque A, et al. Consenso SEDAR-SEMICYUC sobre el manejo de las alteraciones de la hemostasia en los pacientes COVID-19 graves. *Med Intensiva*. 2021;45:567–568.




Figure 1 Schematic representation of the recommendations for the management of anticoagulants and antiplatelet drugs in severe COVID-19 patients.

ASA: acetylsalicylic acid; DOAC: direct oral anticoagulant; AVK: anti-vitamin K; DD: D dimer; VTED: venous thromboembolic disease; AF: atrial fibrillation; GFR: glomerular filtration rate; FIB: fibrinogen; LMWH: low molecular weight heparin; UFH: unfractionated heparin; NR: normal range; HIT: heparin-induced thrombocytopenia; IMV: invasive mechanical ventilation; NIMV: noninvasive mechanical ventilation.

patients where needed, and it is advisable to replace clopidogrel with prasugrel in those cases requiring dual therapy.

Interpretation of the hemostasis tests:

- It is advisable not to administer hemostatic agents to correct the coagulation test data in the absence of significant bleeding.
- In situations of active bleeding, when the administration of hemostatic agents proves necessary, the use of plasma as first choice is suggested versus prothrombin complex concentrates, due to the lack of experience and safety data.
- Routine protocols for the management of bleeding are recommended in COVID-19 patients with severe acute hemorrhage.

We would like to end by underscoring the importance of the early detection and optimum management of hemostatic disorders in severe COVID-19 patients. In our opinion, the establishment of consensuses endorsed by scientific societies allows a better approach to patient management, and should be promoted whenever possible.

Reference

1. Llau JV, Ferrandis R, Sierra P, Hidalgo F, Cassinello C, Gómez-Luque A, et al. Recomendaciones de consenso SEDAR-SEMICYUC

sobre el manejo de las alteraciones de la hemostasia en los pacientes graves con infección por COVID-19. *Rev Esp Anestesiol Reanim.* 2020;67:391–9.

J.V. Llau^{a,b,*}, R. Ferrandis^{a,c}, P. Sierra^{a,d}, F. Hidalgo^{a,e}, C. Cassinello^{a,f}, A. Gómez-Luque^{a,g}, M. Quintana^{h,i}, R. Amezcaga^{h,j}, M. Gerol^{h,k}, A. Serrano^{h,l}, P. Marcos^{h,m}

^a *Sociedad Española de Anestesiología-Reanimación y Terapéutica del Dolor (SEDAR), Spain*

^b *Hospital Universitario Doctor Peset, Valencia, Spain*

^c *Hospital Universitario i Politècnic La Fe, Valencia, Spain*

^d *Fundació Puigver, Barcelona, Spain*

^e *Clínica Universidad de Navarra, Pamplona, Spain*

^f *Hospital Universitario Miguel Servet, Zaragoza, Spain*

^g *Hospital Universitario Virgen de la Victoria, Málaga, Spain*

^h *Sociedad Española de Medicina Intensiva, Crítica y de Unidades Coronarias (SEMICYUC), Spain*

ⁱ *Hospital Universitario La Paz-Carlos III, Madrid, Spain*

^j *Hospital Universitario Son Espases, Palma de Mallorca, Spain*

^k *Hospital Universitario de Burgos, Burgos, Spain*

^l *Hospital Clínico Universitario, Valencia, Spain*

^m *Hospital Germans Trias i Pujol, Badalona, Spain*

* Corresponding author.

E-mail address: juanvllau@gmail.com (J.V. Llau).

2173-5727/ © 2021 Published by Elsevier España, S.L.U.